Streetbeat News

CYBN

Cybin Inc.

https://www.cybin.com

Industry

Biotechnology

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Open

11.82

Mkt cap

232M

Volume

2.1M

High

12.95

P/E Ratio

-2.14

52-wk high

21.66

Low

11.30

Div yield

N/A

52-wk low

6.50

The article discusses recent developments in the field of psychedelic therapies for mental health disorders. Small Pharma's (OTC:DMTTF) Phase 1b study on DMT and SSRIs for major depressive disorder (MDD) has released new findings. TheraPsil, a Canadian non-profit, has launched an MDMA-assisted psychotherapy training program. Apex Labs' psilocybin macrodose drug protocol has been approved for a Canadian veteran's treatment-resistant depression. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has been on a slow downtrend. Other companies mentioned include GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD), Enveric Biosciences (NASDAQ:ENVB), Bright Minds Biosciences (NASDAQ:DRUG), Silo Pharma (NASDAQ:SILO), Atai Life Sciences (NASDAQ:ATAI), FSD Pharma (NASDAQ:HUGE), Incannex Healthcare (NASDAQ:IXHL), Lucy Scientific Discovery (NASDAQ:LSDI), and Cybin Inc. (NYSE:CYBN).

Portfolio Pulse from Lara Goldstein

October 02, 2023 | 1:46 pm

Cybin Inc. (NYSE:CYBN) and psychedelic therapy education organization Fluence have partnered to streamline and scale Cybin's EMBARK facilitator training program for a global Phase 3 trial of deuterated psilocybin analog CYB003 for major depressive disorder treatment. Fluence will assist Cybin in selecting and training facilitators for the trial, produce additional video content, and offer both real-time and self-paced training.

Portfolio Pulse from Lara Goldstein

September 26, 2023 | 7:40 pm

UK-based Small Pharma (OTCQB:DMTTF) has released findings from its Phase 1b study on the interaction of its DMT compound, SPL026, and selective serotonin reuptake inhibitors (SSRIs) for the treatment of major depressive disorder (MDD). The study found that SPL026 was well-tolerated by all 17 patients, with no serious adverse events reported. The treatment showed greater antidepressant effects in the SSRI cohort, suggesting enhanced efficacy when administered jointly with SSRIs. Small Pharma's CEO mentioned exploring these findings as part of the integrated DMT program with Cybin (NYSE:CYBN).

Portfolio Pulse from Lara Goldstein

September 26, 2023 | 6:31 pm

Billionaire Steve Cohen has invested nearly $19 million in Cybin Inc. (NYSE:CYBN) for psychedelics R&D. A new bill in Congress aims to discourage federal intervention in states that legalize or decriminalize psilocybin mushrooms. Enthea, a healthcare benefits administrator, is expanding its network to include psychedelic-assisted therapies in health benefit plans. Magdalena Biosciences, Jaguar Health (NASDAQ:JAGX) and Filament Health (OTC:FLHLF) are developing plant-based medicines for mental health indications. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.70 on Sept. 18, slightly below previous openings.

Portfolio Pulse from Lara Goldstein

September 26, 2023 | 1:28 pm

Cybin has announced an agreement with Fluence to support the scaling of EMBARK training for its CYB003 Phase 3 trial. Fluence will assist in the selection and training of facilitators, create supplemental video content, and provide both asynchronous and synchronous training.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 11:35 am

Cybin (NYSE:CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD). The company has delivered the highest dose of the drug with no serious adverse events reported. Cybin is planning to scale its clinical program around CYB003, which is protected by a U.S. patent until 2041, to a multinational Phase 3 study in early 2024. The company is also anticipating a potential FDA “Breakthrough Therapy” designation in 2023’s last quarter. Additionally, Cybin's acquisition of Small Pharma (OTC:DMTTF) is expected to take place within the last quarter of 2023.

Portfolio Pulse from Lara Goldstein

September 22, 2023 | 2:04 am

Cybin Inc. has completed enrollment in its Phase 2 study of CYB003, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 2:38 pm

Cybin Inc. (NYSE:CYBN) has completed enrollment in its Phase 2 study of CYB003, a treatment for major depressive disorder. The company has reported no serious adverse events and a favorable safety profile. Cybin plans to scale the CYB003 program to a potential Phase 3 study in early 2024. The program is supported by a recently granted U.S. patent and the company anticipates potential Breakthrough Therapy designation, subject to FDA approval, in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 11:32 am

Shares of several companies including TransCode Therapeutics, Fresh Tracks Therapeutics, EBET, Exscientia, Histogen, Rail Vision, Avinger, Inhibikase Therapeutics, Microbot Medical, and Cheche Group are trading higher in pre-market. Fresh Tracks Therapeutics and Histogen announced plans of liquidation and dissolution. Exscientia and Merck announced collaboration on AI-driven drug discovery. Avinger announced the commercial launch of its Tigereye ST image-guided CTO crossing device. On the other hand, shares of ARS Pharmaceuticals, Connexa Sports Technologies, Bird Global, TD Holdings, AgileThought, Elutia, Digital Transformation Opportunities Corp., Cybin, and Revance Therapeutics are trading lower. ARS Pharmaceuticals received a Complete Response Letter from the FDA for its neffy® Epinephrine nasal spray. Bird Global announced its purchase of micromobility operator Skinny Labs for $19 million. Elutia announced a $26 million private placement of shares.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 12:19 pm

Shares of several companies including Connexa Sports Technologies, Elutia, Galera Therapeutics, Senti Biosciences, Neptune Wellness Solutions, Aclarion, Cybin, Avinger, SelectQuote, and Bit Brother Limited are trading higher in pre-market. Elutia's shares rose after the sale of its Orthobiologics business unit to Berkeley Biologics. Galera scheduled a meeting with the FDA to discuss next steps for its radiotherapy avasopasem. Neptune Wellness announced intention to spinout Sprout Organics. Cybin shares surged after hedge fund owner Steve Cohen invested $19 million in the company. On the other hand, shares of Digital Transformation Opportunities Corp., Rocket Lab USA, Novo Integrated Sciences, 60 Degrees Pharmaceuticals, Terran Orbital Corporation, Perspective Therapeutics, MSP Recovery, T2 Biosystems, SCWorx Corp., and FLJ Group Limited are trading lower in pre-market.

Portfolio Pulse from Lisa Levin

September 19, 2023 | 11:59 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.